Mix and Match COVID Boosters: Time Crunch For Data Review May Mean No Advisory Committee Vote

 
• By Sarah Karlin-Smith
  
clock
FDA may not have time to finish reviewing heterologous booster data before the next VRBPAC • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Vaccines

More from Pink Sheet